CU23719A3 - Anticuerpo e inmunoconjugado con actividad neutralizante del virus de la rabia, molécula de ácido nucleico y vector - Google Patents

Anticuerpo e inmunoconjugado con actividad neutralizante del virus de la rabia, molécula de ácido nucleico y vector

Info

Publication number
CU23719A3
CU23719A3 CU20060230A CU20060230A CU23719A3 CU 23719 A3 CU23719 A3 CU 23719A3 CU 20060230 A CU20060230 A CU 20060230A CU 20060230 A CU20060230 A CU 20060230A CU 23719 A3 CU23719 A3 CU 23719A3
Authority
CU
Cuba
Prior art keywords
virus
nucleic acid
immunocate
rabia
antibody
Prior art date
Application number
CU20060230A
Other languages
English (en)
Inventor
Robert Arjen Kramer
Kruif Cornelis Adriaan De
Willem Egbert Marissen
Alexander Berthold Hendrik Bakker
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Publication of CU23719A3 publication Critical patent/CU23719A3/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)

Abstract

La presente invención proporciona anticuerpos que se enlazan específicamente al virus de la rabia y son capaces de neutralizar el virus. La invención además proporciona inmunoconjugados que comprenden dichos anticuerpos, moléculas de ácido nucleico que codifican los anticuerpos y vectores conteniendo dichas moléculas. Los anticuerpos están dirigidos al diagnóstico, profilaxis y/o tratamiento de una condición que resulta del virus de la rabia. Preferiblemente, estos pueden usarse en profilaxis de exposición posterior de la rabia.
CU20060230A 2004-05-27 2006-11-27 Anticuerpo e inmunoconjugado con actividad neutralizante del virus de la rabia, molécula de ácido nucleico y vector CU23719A3 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US57502304P 2004-05-27 2004-05-27
EP2004050943 2004-05-27
EP2004051661 2004-07-29
EP2004052286 2004-09-23
EP2004052772 2004-11-03
EP2005050310 2005-01-25
EP2005050953 2005-03-03

Publications (1)

Publication Number Publication Date
CU23719A3 true CU23719A3 (es) 2011-10-14

Family

ID=34968690

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20060230A CU23719A3 (es) 2004-05-27 2006-11-27 Anticuerpo e inmunoconjugado con actividad neutralizante del virus de la rabia, molécula de ácido nucleico y vector

Country Status (23)

Country Link
US (5) US7579446B2 (es)
EP (3) EP2314620B1 (es)
JP (1) JP4768730B2 (es)
KR (2) KR101228157B1 (es)
CN (5) CN102212131B (es)
AT (1) ATE501171T1 (es)
AU (1) AU2005250163B2 (es)
BR (1) BRPI0511479C1 (es)
CA (1) CA2568162C (es)
CU (1) CU23719A3 (es)
CY (1) CY1111550T1 (es)
DK (1) DK1749029T3 (es)
EA (1) EA010785B1 (es)
ES (2) ES2468021T3 (es)
HK (3) HK1094705A1 (es)
HR (3) HRP20110320T1 (es)
IL (3) IL179586A (es)
MX (1) MXPA06013482A (es)
NZ (2) NZ550366A (es)
PL (3) PL1749029T3 (es)
PT (3) PT2314620E (es)
RS (2) RS53269B (es)
WO (1) WO2005118644A2 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
DE60317677T2 (de) * 2002-06-13 2008-10-30 Crucell Holland B.V. Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung
EP1539235A2 (en) 2002-07-01 2005-06-15 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
CA2872136C (en) 2002-07-18 2017-06-20 Merus B.V. Recombinant production of mixtures of antibodies
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
CA2527694C (en) 2003-05-30 2015-07-14 Hendricus Renerus Jacobus Mattheus Hoogenboom Fab library for the preparation of anti vegf and anti rabies virus fabs
CA2526284C (en) 2003-06-25 2014-11-18 Crucell Holland B.V. Binding molecules for the treatment of myeloid cell malignancies
KR101206206B1 (ko) * 2003-07-22 2012-11-29 크루셀 홀란드 비.브이. 사스-코로나바이러스에 대한 결합분자 및 그것의 용도
CA2568162C (en) 2004-05-27 2013-04-16 Crucell Holland B.V. Binding molecules capable of neutralizing rabies virus and uses thereof
EP1799259B1 (en) * 2004-10-12 2012-12-05 Crucell Holland B.V. Binding molecules for the detection of cancer
AU2006245734C1 (en) 2005-05-12 2012-05-24 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
US8642513B2 (en) * 2005-09-15 2014-02-04 Crucell Holland B.V. Method for preparing immunoglobulin libraries
US7807645B2 (en) 2005-09-23 2010-10-05 The Regents Of The University Of California Method of treating degenerative disorders of the nervous system by administration of fibrinogen fragment
EP2024394B1 (en) 2006-06-06 2014-11-05 Crucell Holland B.V. Human binding molecules having killing activity against enterococci and staphylococcus aureus and uses thereof
EA018030B1 (ru) 2006-06-06 2013-05-30 Круселл Холланд Б.В. Связывающие молекулы человека, имеющие убивающую активность против стафилококков, и их применения
WO2008028946A2 (en) 2006-09-07 2008-03-13 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
EP2088997B1 (en) * 2006-12-05 2016-08-24 Janssen Vaccines & Prevention B.V. Liquid anti-rabies antibody formulations
WO2009000099A2 (en) 2007-06-25 2008-12-31 Esbatech Ag Methods of modifying antibodies, and modified antibodies with improved functional properties
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
US8877199B2 (en) 2009-05-15 2014-11-04 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services B cell surface reactive antibodies
US8821879B2 (en) 2009-09-04 2014-09-02 Xoma Technology Ltd. Anti-botulism antibody coformulations
EP2483416B1 (en) * 2009-10-02 2016-11-23 The Regents of The University of California Monoclonal antibodies
CN101696242B (zh) * 2009-10-26 2011-12-28 中国人民解放军南京军区军事医学研究所 人源抗狂犬病毒中和抗体Fab及其制备方法和应用
EP2521735A2 (en) * 2010-01-04 2012-11-14 Indian Immunologicals Limited Recombinant human bivalent diabody against rabies virus and uses thereof
EP2894221B1 (en) * 2010-02-19 2017-10-11 Japan Science and Technology Agency Human abzyme
CA3101298A1 (en) 2010-03-01 2011-09-09 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
CN103003307B (zh) 2010-03-10 2017-08-11 根马布股份公司 抗c‑MEt的单克隆抗体
WO2011159835A1 (en) * 2010-06-16 2011-12-22 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Antibodies to endoplasmin and their use
KR101388680B1 (ko) * 2011-03-18 2014-04-28 (주)셀트리온 광견병 바이러스를 중화시킬 수 있는 결합 분자
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
KR101495019B1 (ko) 2011-09-30 2015-02-24 (주)셀트리온 광견병 바이러스를 중화시킬 수 있는 결합 분자
ES2743399T3 (es) 2012-04-20 2020-02-19 Merus Nv Métodos y medios para la producción de moléculas heterodiméricas similares a Ig
CN102924571A (zh) * 2012-10-29 2013-02-13 复旦大学 狂犬病毒糖蛋白与核蛋白的抗原表位多肽及其筛选、鉴定方法与应用
CN105814077B (zh) * 2013-12-12 2019-07-26 赛特瑞恩股份有限公司 能够中和狂犬病毒的结合分子
CN103954777A (zh) * 2014-05-20 2014-07-30 北京凯思百奥科技发展有限公司 一种狂犬病病毒单克隆抗体及其应用
RU2549971C1 (ru) * 2014-07-01 2015-05-10 Федеральное казённое учреждение здравоохранения Ставропольский научно-исследовательский противочумный институт Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Способ консервации иммунопероксидазного конъюгата
CN104761640A (zh) * 2015-02-03 2015-07-08 中国食品药品检定研究院 具有中和活性的抗狂犬病病毒单克隆抗体的制备及应用
US10722571B2 (en) * 2015-06-10 2020-07-28 Celltrion Inc. Rabies virus G protein epitope, and rabies virus neutralising binding molecule that binds specifically thereto
EP3402518A4 (en) 2016-01-14 2019-07-03 Memorial Sloan-Kettering Cancer Center PEPTIDES SPECIFIC T-CELL RECEPTOR-SIMILAR ANTIBODIES, DERIVED FROM FOXP3
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
RU2718835C2 (ru) * 2017-12-29 2020-04-15 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Нейтрализующее моноклональное антитело, связывающееся с гликопротеином g вируса бешенства, фрагменты днк, кодирующие указанное антитело, и антигенсвязывающий фрагмент
WO2019227039A1 (en) * 2018-05-24 2019-11-28 Lankenau Institute For Medical Research Compositions comprising antibodies to rabies virus and the uses thereof
CN110317267B (zh) * 2018-08-09 2020-11-20 北京智仁美博生物科技有限公司 针对狂犬病病毒的双特异性抗体及其用途
KR20220006085A (ko) * 2019-05-30 2022-01-14 샨동 보안 바이오테크놀로지 컴퍼니, 리미티드 클라우딘(Claudin) 18.2를 표적화하는 항체 또는 키메라 항원 수용체
CN111171145B (zh) * 2020-01-21 2021-11-05 兰州生物制品研究所有限责任公司 一种抗狂犬病病毒单克隆抗体、制备方法及用途
TW202305001A (zh) * 2021-04-09 2023-02-01 美商索倫多醫療公司 結合ror1之抗原結合蛋白
CN114397453B (zh) * 2022-03-25 2022-06-07 江苏美克医学技术有限公司 新型冠状病毒突变株的检测试剂盒及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
ES2062364T3 (es) * 1989-06-08 1994-12-16 Wistar Inst Un metodo de preparacion de una composicion para el tratamiento despues de la exposicion de infeccion de rabia.
US6248574B1 (en) 1989-12-13 2001-06-19 Avigdor Shaffermann Polypeptides selectively reactive with antibodies against human immunodeficiency virus and vaccines comprising the polypeptides
DE4006630A1 (de) * 1990-03-03 1991-09-12 Behringwerke Ag Humane monoklonale antikoerper gegen tollwutviren, ihre herstellung und verwendung
NL9101953A (nl) 1991-11-21 1993-06-16 Seed Capital Investments Testinrichting omvattende een plaat met een veelvoud van putjes met een bijbehorende doseerinrichting, alsmede een kit die deze inrichtingen omvat en toepassing van de inrichtingen.
US5624949A (en) 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
DE69718341T2 (de) * 1996-10-08 2003-10-30 Bisys B V U Verfahren und mittel zur auswahl von peptiden und proteinen mit spezifischer affinität zu einem zielmolekül
SI1533380T1 (sl) 1999-04-15 2010-03-31 Crucell Holland Bv Proizvajanje rekombinantnega proteina v človeški celici ki obsega vsaj en protein E adenovirusa
US20040013672A1 (en) * 2000-05-16 2004-01-22 Thomas Jefferson University Recombinant antibodies, and compositions and methods for making and using the same
US7071319B2 (en) * 2000-05-16 2006-07-04 Thomas Jefferson University Recombinant antibodies, and compositions and methods for making and using the same
DK1402025T3 (da) 2001-06-15 2006-06-06 Crucell Holland Bv Kimære fager
CA2457362C (en) * 2001-08-21 2012-01-17 Thomas Jefferson University Human monoclonal rabies virus neutralizing antibodies, and methods for making and using the same
DE60317677T2 (de) * 2002-06-13 2008-10-30 Crucell Holland B.V. Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung
CA2872136C (en) * 2002-07-18 2017-06-20 Merus B.V. Recombinant production of mixtures of antibodies
US20100069614A1 (en) * 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
CA2526284C (en) 2003-06-25 2014-11-18 Crucell Holland B.V. Binding molecules for the treatment of myeloid cell malignancies
KR101206206B1 (ko) * 2003-07-22 2012-11-29 크루셀 홀란드 비.브이. 사스-코로나바이러스에 대한 결합분자 및 그것의 용도
JP5744369B2 (ja) 2004-02-27 2015-07-08 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ＩＬ１５−Ｒα用ＩＬ−１５結合部位およびアゴニスト／アンタゴニスト活性を有する特異的ＩＬ−１５突然変異体
CA2568162C (en) * 2004-05-27 2013-04-16 Crucell Holland B.V. Binding molecules capable of neutralizing rabies virus and uses thereof
EP1812067B1 (en) 2004-11-11 2012-03-21 Crucell Holland B.V. Compositions against sars-coronavirus and uses thereof
CA2591665C (en) 2004-12-20 2015-05-05 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
ES2407468T3 (es) 2005-04-18 2013-06-12 Yeda Research And Development Company Limited Formulaciones de anticuerpos anti-hepatitis B (HBV) estabilizadas
AU2006245734C1 (en) 2005-05-12 2012-05-24 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
WO2006136601A1 (en) 2005-06-23 2006-12-28 Crucell Holland B.V. Optimization of west nile virus antibodies
CA2643838A1 (en) * 2006-02-27 2007-09-07 Elan Pharmaceuticals, Inc. Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by vla-4
EP2024394B1 (en) * 2006-06-06 2014-11-05 Crucell Holland B.V. Human binding molecules having killing activity against enterococci and staphylococcus aureus and uses thereof
EA018030B1 (ru) * 2006-06-06 2013-05-30 Круселл Холланд Б.В. Связывающие молекулы человека, имеющие убивающую активность против стафилококков, и их применения
WO2008028946A2 (en) * 2006-09-07 2008-03-13 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
EP2088997B1 (en) * 2006-12-05 2016-08-24 Janssen Vaccines & Prevention B.V. Liquid anti-rabies antibody formulations

Also Published As

Publication number Publication date
US20100272724A1 (en) 2010-10-28
KR101456770B1 (ko) 2014-10-31
CA2568162A1 (en) 2005-12-15
PL1749029T3 (pl) 2011-08-31
WO2005118644A2 (en) 2005-12-15
NZ550366A (en) 2009-11-27
ES2468021T3 (es) 2014-06-13
CN1961002B (zh) 2011-05-18
CN102241769B (zh) 2016-08-10
CN102212131A (zh) 2011-10-12
US20100310572A1 (en) 2010-12-09
EP2314620B1 (en) 2013-06-05
HRP20130750T1 (hr) 2013-10-11
CN102139106A (zh) 2011-08-03
CN102212131B (zh) 2013-05-08
CN102241769A (zh) 2011-11-16
HK1159651A1 (en) 2012-08-03
HRP20110320T1 (hr) 2011-05-31
US7740852B2 (en) 2010-06-22
CN102139106B (zh) 2014-10-08
AU2005250163B2 (en) 2011-08-25
EP1749029B1 (en) 2011-03-09
PT2314620E (pt) 2013-09-02
RS51847B (en) 2012-02-29
US20070072177A1 (en) 2007-03-29
EP2314620A1 (en) 2011-04-27
CA2568162C (en) 2013-04-16
CN1961002A (zh) 2007-05-09
HK1094705A1 (en) 2007-04-04
EA200602210A1 (ru) 2007-04-27
HRP20140419T1 (hr) 2014-06-06
KR20130010130A (ko) 2013-01-25
MXPA06013482A (es) 2007-03-01
JP2008508859A (ja) 2008-03-27
BRPI0511479C1 (pt) 2021-05-25
HK1157680A1 (en) 2012-07-06
JP4768730B2 (ja) 2011-09-07
KR101228157B1 (ko) 2013-01-31
EP1749029A2 (en) 2007-02-07
PT1749029E (pt) 2011-06-27
EP2314621A1 (en) 2011-04-27
US20080070799A1 (en) 2008-03-20
PL2314620T3 (pl) 2013-11-29
AU2005250163A1 (en) 2005-12-15
EA010785B1 (ru) 2008-10-30
KR20070044807A (ko) 2007-04-30
IL179586A0 (en) 2007-05-15
US9005624B2 (en) 2015-04-14
PT2314621E (pt) 2014-06-23
DK1749029T3 (da) 2011-06-06
NZ580607A (en) 2011-05-27
IL225849A0 (en) 2013-06-27
US8148497B2 (en) 2012-04-03
ES2426725T3 (es) 2013-10-24
WO2005118644A3 (en) 2006-03-09
BRPI0511479A (pt) 2007-12-26
PL2314621T3 (pl) 2014-08-29
IL201970A (en) 2014-06-30
US20080226652A1 (en) 2008-09-18
RS53269B (en) 2014-08-29
BRPI0511479B1 (pt) 2019-01-29
US7579446B2 (en) 2009-08-25
IL179586A (en) 2013-06-27
EP2314621B1 (en) 2014-03-05
CY1111550T1 (el) 2015-08-05
CN102212132A (zh) 2011-10-12
ATE501171T1 (de) 2011-03-15

Similar Documents

Publication Publication Date Title
CU23719A3 (es) Anticuerpo e inmunoconjugado con actividad neutralizante del virus de la rabia, molécula de ácido nucleico y vector
EA200801509A1 (ru) Человеческие моноклональные антитела к протеинтирозинкиназе 7 ( ptk7) и способы применения антител против ptk7
CY1123030T1 (el) Υλικο και μεθοδοι για θεραπεια ή αποτροπη σχετικων me her-3 ασθενειων
EA200800953A1 (ru) Человеческие моноклональные антитела к cd70
EA200870021A1 (ru) Человеческие моноклональные антитела к фукозил-gm1 и способы применения анти-фукозил-gm1 антител
CL2014003637A1 (es) Anticuerpo monoclonal optimizado que se une al gen 3 de activación de linfocitos (lag-3); molécula biespecífica que lo comprende; inmunoconjugado que comprende el anticuerpo unido a un agente terapéutico; composición; ácido nucleico; vector; célula huésped; método de preparación; y uso para inhibir el crecimiento de un tumor o tratar una infección viral.
CY1119454T1 (el) Αντισωματα εναντι cd38 για τη θεραπεια του πολλαπλου μυελωματος
CY1117859T1 (el) Αντισωματα και ανοσοσυζευγματα anti-cd79b και μεθοδοι χρησης
PE20190398A1 (es) Anticuerpos nuevos que se unen especificamente a los epitopos del virus del zika y usos de los mismos
CO7151488A2 (es) Anticuerpos de reacción cruzada anti-jagged1/jagged 2, anticuerpos anti-jagged activables y métodos de uso de los mismos
EA200800229A1 (ru) Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1)
EA200970477A1 (ru) Человеческие моноклональные антитела к btla и способы применения
AR103868A1 (es) Anticuerpos anti-cd47 como agentes terapéuticos
AR107444A1 (es) Composición farmacéutica que comprende constructos de anticuerpo biespecíficos
AR083293A1 (es) Agentes de union a cd33
CO6351802A2 (es) Anticuerpos para ccr2
CY1115700T1 (el) Αντισωματα και ανοσοσυζευγματα αντι-cd79b και μεθοδοι χρησης
EA201171383A1 (ru) Человеческие связывающие молекулы, обладающие способностью нейтрализовывать вирус гриппа h3n2, и их применение
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
CL2008002153A1 (es) Anticuerpo aislado o fragmanto de unión de antigeno del mismo que se une al receptor de il-18 (il-18r); molecula de ácido nucleico codificante; celula huesped que la comprende; composición farmaceutica; uso médico para tratar o prevenir una condición asociada con il-18r; método in vitro para inhibir la unión de il-18 al il-18r.
CY1113089T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα σε ειδικο προστατικο μεμβρανικο αντιγονο (psma)
NO20076157L (no) Anti-TRKB monoklonale antistoffer og anvendelser derav
NO20083053L (no) Humane monoklonale antistoffer mot O8E
AR086272A2 (es) Anticuerpos anti-factor d humanizados y sus usos
CY1114603T1 (el) ΑΝΤΙΣΩΜΑ ΕΝΑΝΤΙΟΝ PDGFR-α ΓΙΑ ΧΡΗΣΗ ΣΤΗΝ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΟΓΚΩΝ

Legal Events

Date Code Title Description
FD Lapse (for not paying fees)